Bariatric Biobank of Manitoba, Canada
Objective: The Manitoba Bariatric Surgery Biobank will store blood, adipose tissue and skeletal muscle samples collected from patients during bariatric surgery. Biomarker profiles will be determined and compared to those of samples collected 1- and 2-years following surgery. One of our objectives is to evaluate the relationship of clinical and metabolic factors as well as adipokine and cytokine profiles on pre- and post- excess body weight loss (1-year and 2-year) and remission/relapse of bariatric surgery outcomes (Type 2 diabetes mellitus, hypertension, dyslipidemia, depression). Being able to determine a pattern in biomarker profiles that may predict diabetes recidivism or failure of excess weight loss following bariatric surgery will provide the opportunity to tailor healthcare delivery to individual needs. The breadth of the negative impacts of obesity, including increased morbidity and mortality, reduction in quality of life, and substantial health care expenditures provides the impetus to discover innovative, integrated, and effective clinical treatment strategies and to build infrastructure that supports collaborative multidisciplinary research. The Manitoba Bariatric Biobank will be a pivotal contribution to surgical research and is an innovative approach to facilitating collaborative research with significant disruptive potential.
| Registered Biobank Name | Bariatric Biobank of Manitoba |
| Biobank Leader | Dr. Krista Hardy |
| Country | Canada |
| Email for biobank inquiries | khardy@sbgh.mb.ca |
| Principal Investigator | Dr. Krista Hardy |
User Type
|